Company intelligence / Profile preview

Flag Bio, Inc.

East Aurora, New York, United Statesgatesfoundation.org ↗

Ownership: Private
Development stage: Preclinical

Overview

As of October 2022, Flag Bio received a $1.98M grant from the Bill & Melinda Gates Foundation to develop new innate immune activation approaches to protect against infectious pathogens in the developing world. The project is focused on creating novel technology platform capabilities and is likely at an early/preclinical stage.

Therapeutic areas: Infectious Diseases
Modalities: Innate immune activation approaches
Industry: Biotech

Drug pipeline

4 assets

LINE-1 retrotransposon vaccine

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Bill & Melinda Gates Foundation (grant partner)

Beyond the preview

Go deeper on Flag Bio, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flag Bio, Inc..

Explore the full profile